117 S3553 IS: Agility in Manufacturing Preparedness Act U.S. Senate 2022-02-02 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II117th CONGRESS2d SessionS. 3553IN THE SENATE OF THE UNITED STATESFebruary 2, 2022Mr. Rubio (for himself and Mr. Coons) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsA BILLTo review domestic biopharmaceutical manufacturing capabilities in order to improve public health and medical preparedness and response capabilities and domestic biopharmaceutical manufacturing capabilities.

1.

Short title

This Act may be cited as the Agility in Manufacturing Preparedness Act.

2.

Review of domestic biopharmaceutical manufacturing capabilities

(a)

In general

The Secretary of Health and Human Services (referred to in this section as the Secretary), in cooperation with the Director of the Biomedical Advanced Research and Development Authority, shall seek to enter into an agreement with the National Institute for Innovation in Manufacturing Biopharmaceuticals to perform the services described in subsection (b).(b)

Review and recommendations

Under an agreement described in subsection (a) between the Secretary, the Director of the Biomedical Advanced Research and Development Authority, and the National Institute for Innovation in Manufacturing Biopharmaceuticals, the National Institute for Innovation in Manufacturing Biopharmaceuticals shall—(1)review current domestic biopharmaceutical manufacturing capacity at the Department of Health and Human Services and its adaptability to various threats; (2)draft recommendations for developing, demonstrating, deploying, and advancing new domestic biopharmaceutical manufacturing technologies that address gaps identified under paragraph (1) and align Federal technologies with technologies available to the private sector, including through the new BioMAP initiative of the Biomedical Advanced Research and Development Authority; and(3)identify other opportunities and priorities to improve the United States public health and medical preparedness and response capabilities and domestic biopharmaceutical manufacturing capabilities.